EPCAM and neoplasm: EpCAM-positive Liver-CSCs—whether detected as circulating tumor cells (CTCs) or within the TME—consistently associate with unfavorable prognosis, including reduced recurrence-free survival (RFS) and overall survival (OS) after curative resection (110–115).